Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics
Authors' conclusion
Up to one-third of participants discontinued either an SGLT-2i or GLP-1RA within 12 months of initiating.
Study context
- Population
- Persons with T2DM and atherosclerotic CVD treated in US cardiology clinicsenrolled 7/2019 to 5/2022
- Participants
- 1,045 persons
- Comparison
- SGLT-2i vs GLP-1RA
- SGLT-2in = 290
- GLP-1RAn = 118
- Primary endpoint
- Frequency and reasons for discontinuation of SGLT2i or GLP-1RA
Primary result
As reported in the abstract
Discontinuation
Further findings
| Outcome | P value |
|---|---|
| Medicare coverage, discontinuing vs persistingDiscontinuing vs Persisting · SGLT-2i: 71.4 vs. 58.1% | P = 0.058 |
| Medicare coverage, discontinuing vs persistingDiscontinuing vs Persisting · GLP-1RA: 71.1 vs. 49.4% | P = 0.027 |
Race, age and sex among those discontinuing
- Race, age and sex did not differ among those discontinuing either class
Original publication
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics. Am Heart J. Published 21 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →